-Ignyte Acquisition closed its IPO of 5.75 million units, including the full 750,000 units subject to the underwriters over-allotment option. Units trade on the Nasdaq under IGNYU.
The new SPAC is focused on the life sciences, biotechnology and healthcare sectors. Read more.
